Indivior Plc Redomiciles to U.S. to Strengthen Market Presence and Governance

Indivior's Strategic Shift: Redomiciliation to Enhance U.S. Presence

Indivior PLC announces a pivotal transition in its corporate structure, intending to shift its domicile from the United Kingdom to the United States. This move involves the establishment of a new parent company, Indivior Pharmaceuticals, Inc. (IPI), in Delaware, which reflects the company’s strategic focus on strengthening its footprint in the U.S. market. The decision follows Indivior's successful listing on the Nasdaq in June 2023 and the planned cancellation of its secondary listing on the London Stock Exchange in July 2025. The company’s board believes that redomiciliation will not only enhance its presence in U.S. capital markets but also streamline corporate governance, positioning Indivior as a leading innovator in the treatment of opioid use disorder.

The redomiciliation process will be executed through a U.K. court-sanctioned scheme of arrangement, pending approval from shareholders at an extraordinary general meeting (EGM) scheduled for early December 2025. Each shareholder will receive one share of IPI for every share of Indivior PLC they hold, with existing Indivior shares cancelled after the exchange. The anticipated effective date for the scheme is late January 2026, when the new IPI shares will commence trading on Nasdaq under the ticker symbol INDV. This strategic maneuver aims to maximize the benefits of Indivior's U.S. listing, creating opportunities for improved equity indexation and fostering closer collaboration with public health leaders, particularly in addressing opioid addiction.

Furthermore, Indivior emphasizes that no additional equity will be raised during this transition, alleviating immediate concerns for shareholders. A shareholder circular, set to be issued in mid-November 2025, will provide detailed information regarding the EGM and the subsequent impacts of the scheme. This initiative reflects Indivior’s commitment to enhancing its operational efficiency and solidifying its role in the public health sector, specifically through its flagship product, SUBLOCADE®, a treatment designed for opioid use disorder.

Indivior's move to reestablish its corporate identity in the U.S. marks a significant milestone in its strategic development, aligning with broader industry trends that favor localized governance and market engagement. The company's efforts to expand its influence in the U.S. market signify its dedication to addressing the urgent needs associated with opioid addiction and improving patient outcomes through innovative treatment options.